指南与共识其他结缔组织病

2015 EULAR/ACR 风湿性多肌痛管理推荐在临床实践中的实施研究

Study on the implementation of the 2015 EULAR/ACR recommendations for polymyalgia rheumatica in clinical practice.
指南 / 共识 · RMD Open · 2026-10-01

该研究通过在线问卷(28 题)调查 EULAR PMR 与巨细胞动脉炎研究组成员及其邀请的全科医生,共获 37 国 308 份回复(211 名风湿科医生、73 名全科医生)。结果显示风湿科医生对 2015 EULAR/ACR 推荐的依从率(83%)高于全科医生(35%),在糖皮质激素起始剂量、甲氨蝶呤使用及 IL-6 受体抑制剂经验方面差异明显。结论认为推荐实施仍不完整,尤其在全科医生中。

要点

  • 风湿科医生对 2015 EULAR/ACR PMR 推荐的依从率为 83%,全科医生仅 35%。
  • 95% 风湿科医生使用甲氨蝶呤作为糖皮质激素节约剂,全科医生仅 26%。
  • 70% 风湿科医生有 IL-6 受体抑制剂用于 PMR 的经验,全科医生仅 2%。

核心结论

  • 2015 EULAR/ACR 风湿性多肌痛管理推荐在临床实践中的实施仍不完整,尤其在全科医生中。
  • 未来推荐更新应纳入促进推荐在管理该疾病的所有专业人员中传播与实施的项目。

研究设计与样本

  • 研究为在线问卷调查(Survey Monkey),含 28 个问题,发放给 EULAR PMR 与巨细胞动脉炎研究组成员(n=375)。
  • 每位成员被要求邀请至少一名有 PMR 经验的全科医生参与(滚雪球法)。
  • 统计分析包括描述性统计,差异检验采用 Fisher 精确检验。

主要发现

  • 共收到来自 37 个国家的 308 份回复,包括 211 名风湿科医生和 73 名全科医生的数据。
  • 风湿科医生对 2015 EULAR/ACR 推荐的依从率(83%)高于全科医生(35%)。
  • 风湿科医生(96%)在推荐范围内剂量起始糖皮质激素的比例高于全科医生(84%)。
  • 在减量方面,风湿科医生(83%)与全科医生(72%)在 4-8 周达到建议的泼尼松等效 10 mg 的比例相似。
  • 几乎全部风湿科医生(95%)使用甲氨蝶呤作为糖皮质激素节约剂,全科医生仅 26%;70% 风湿科医生有 IL-6 受体抑制剂用于 PMR 的经验,全科医生仅 2%。

关键数值与推荐

  • 2015 EULAR/ACR 推荐依从率:风湿科医生 83%,全科医生 35%。
  • 糖皮质激素起始剂量在推荐范围内:风湿科医生 96%,全科医生 84%。
  • 4-8 周达到泼尼松等效 10 mg 的减量比例:风湿科医生 83%,全科医生 72%。
  • 甲氨蝶呤作为糖皮质激素节约剂的使用:风湿科医生 95%,全科医生 26%。
  • IL-6 受体抑制剂用于 PMR 的经验:风湿科医生 70%,全科医生 2%。

临床怎么用

  • 应加强全科医生对 2015 EULAR/ACR PMR 管理推荐的培训与推广,以提高依从性。
  • 全科医生在 PMR 患者中甲氨蝶呤和 IL-6 受体抑制剂的使用经验明显不足,需针对性教育。
  • 随访安排上,风湿科医生更倾向预约随访(99% vs 82%),全科医生更倾向短间隔随访(47% vs 31%),需统一随访策略。

局限性

  • 研究为在线问卷调查,可能存在选择偏倚和应答偏倚。
  • 全科医生样本通过滚雪球法招募,代表性有限。
  • 依从性基于医生自我报告,未与患者实际管理数据核实。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To study the implementation of the 2015 European Alliance of Associations for Rheumatology (EULAR)/American College of Rheumatology (ACR) management recommendations for polymyalgia rheumatica (PMR) among rheumatologists and general practitioners (GPs). METHODS: An online survey (Survey Monkey) comprising 28 questions was distributed among members of the EULAR Study Group on PMR and giant cell arteritis (n=375). Each member was asked to invite at least one GP (snowball principle) with experience in PMR to participate. Statistical analysis included descriptive statistics; differences were tested using Fisher's exact test. RESULTS: There were 308 respondents from 37 countries including data from 211 rheumatologists and 73 GPs. Adherence to the 2015 EULAR/ACR recommendations was higher among rheumatologists (83%) than GPs (35%). Rheumatologists (96%) prescribed glucocorticoids more frequently at dosages within the recommended range than GPs (84%). Concerning tapering, a similar proportion of rheumatologists (83%) and GPs (72%) reached the suggested 10 mg prednisone equivalent after 4-8 weeks. Almost all rheumatologists used methotrexate as a glucocorticoid-sparing agent (95%) as compared with only 26% of GPs. Similarly, 70% of rheumatologists, but only 2% of GPs, had experience with interleukin-6 receptor inhibitors for PMR. For follow-up, more rheumatologists preferred scheduled (as opposed to on demand) visits than GPs (99% vs 82%), while more GPs than rheumatologists (47% vs 31%) planned a short follow-up interval (4-8 weeks) in the first year of disease. CONCLUSION: Implementation of the EULAR/ACR recommendation for the management of PMR remains incomplete, particularly among GPs. Future updates should incorporate projects to foster diffusion and implementation of the recommendations among all professionals managing this disease.

来源:RMD Open,查看原文。版权归原作者所有。

引用

  1. di Lernia M, Thuere KL, Sattui SE, et al. Study on the implementation of the 2015 EULAR/ACR recommendations for polymyalgia rheumatica in clinical practice. RMD Open. 2026. PMID: 42823100. doi:10.1136/rmdopen-2026-007295

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。